This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Reducing Migraine Pain: New Therapeutic Options to Enhance Patient Care

Reducing Migraine Pain: New Therapeutic Options to Enhance Patient Care

Format

Webcast

Time to Complete

1 hour

Released

July 19, 2019

Expires

July 19, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Jointly provided by Boston University School of Medicine and Rockpointe

Commercial Supporter

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Program Description

Patients with migraine can unfortunately experience misdiagnoses and inadequate treatments based on the challenges of differentiating migraine from other types of headache. Once diagnosed, several innovative agents have recently been approved to enhance the outcomes of patients with migraine. However, chronic migraine management remains challenging, as many patients will require multiple therapies.

This CME activity, “Reducing Migraine Pain: New Therapeutic Options to Enhance Patient Care,” will help participants better distinguish migraine from other types of headache, explain the pathophysiology of migraine, and review the latest safety and efficacy data on new and emerging therapies for migraine prevention.

Intended Audience

The intended audience for this educational initiative is primary care physicians (PCPs), such as internal medicine specialists and family medicine physicians, the frontline clinicians responsible for the diagnosis and management of patients with migraines.

Educational Objectives

This program is designed to address ACGME and IOM competencies, including delivering patient-centered care, practicing evidence-based medicine, and focusing on quality improvement.

At the conclusion of this activity, participants should be able to:

  • Distinguish between migraine and other types of headache utilizing diagnostic criteria
  • Explain the pathophysiology of migraine, including the role of calcitonin gene-related peptide (CGRP)
  • Recognize how to individualize migraine management through the use of pharmacologic and nonpharmacologic treatments, as well as preventive therapies
  • Assess the clinical efficacy and safety data of new and emerging therapeutic agents for the prevention of migraines

Fee Information

There is no fee for this activity.

Conflict of Interest Disclosure Policy

This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

M. Susan Burke, MD, FACP
Clinical Associate Professor of Medicine
Sidney Kimmel Medical College at Thomas Jefferson University
Senior Advisor, Lankenau Medical Associates
Lankenau Medical Center
Wynnewood, PA

Dr. Burke discloses the folowing:
Consultant: Radius;
Speaker's Bureau: Merck

Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, NH
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Dr. Tepper discloses the following:
Grant/Research Support: Alder, Allergan, Amgen, ATI, Dr. Reddy’s, ElectroCore, eNeura, Neurolief, Scion Neurostim, Teva, Zosano;
Consultant/Advisory Board: Acorda, Alder, Alexsa, Allergan, Alphasights, Amgen, ATI, Axsome Therapeutics, Biohaven, Cefaly, Charleston Labs, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, ExpertConnect, GLG, Guidepoint Global, GSK, Impel, Magellan Rx Management, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Sudler and Hennessey, Supernus, Teva, Theranica, Trinity Partners, XOC, Zosano;
Stockholder: ATI; Royalties: Springer

Brian E. McGeeney, MD, MPH, MBA (CME Course Director) discloses the following:
Consultant: Alder, Pernix, and Promius

Accredited Provider Disclosure

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Nicolle Rochino, PharmD, RPh; Blair St. Amand; Elizabeth Drury; Natalie Sanfratello, MPH; and Jason Worcester, MD have nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

Instructions

To obtain credit, a score of 67% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For information about the accreditation of this program, please email: cme@bu.edu.

If you have any other questions relating to your certificate or other issues with the activity, please contact myCME.Support@haymarketmedical.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue